Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

OKYO Pharma Limited - Ordinary Shares (NQ:OKYO)

2.568 -0.242 (-8.60%)
Streaming Delayed Price Updated: 3:58 PM EDT, Jul 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about OKYO Pharma Limited - Ordinary Shares

< Previous 1 2 3 Next >
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
Top-line Efficacy and Safety Data on Track for Release in December 2023 
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma’s Advancing Clinical Mission to Better Treat Eye Disease Sends Shares 89% Higher Since August ($OKYO)
Via AB Newswire
OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Limited Announces Withdrawal of Public Offering
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Public Offering of Ordinary Shares
From OKYO Pharma LTD
Via GlobeNewswire
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END 
Via FinancialNewsMedia
OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Limited Announces Withdrawal of Public Offering
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Proposed Public Offering of Ordinary Shares
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Limited Receives Nasdaq Deficiency Notice
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform
Webull’s community of active participants can now access OKYO's profile on the leading mobile-first brokerage platform 
From OKYO Pharma LTD
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.